Spanish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
gastrointestinal stromal tumors/edema
El enlace se guarda en el portapapeles.
Página 1 desde 71 resultados
Metastatic cerebellar gastrointestinal stromal tumor with obstructive hydrocephalus arising from the small intestine: a case report and review of the literature.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
Gastrointestinal stromal tumor (GIST) is defined as a c-kit-positive gastrointestinal, mesenteric, or omental mesenchymal tumor that very rarely metastasizes to the brain. Metastasis to the cerebellum is particularly rare. An 80-year-old man presented with nausea and vomiting with disturbance of
[Long-term progression-free survival after reduction surgery and postoperative low-dose imatinib administration for multiple liver metastases of duodenal gastrointestinal stromal tumor].
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
A fifty-six year-old woman visited our institute, suffering from lower abdominal pain. A tumor was palpable in the pelvic cavity, having the diameter of 9.7 cm, as measured by transvaginal ultrasonography (US). Computed tomography and magnetic resonance imaging (MRI) revealed a high
[Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE
To evaluate the efficacy and safety of imatinib mesylate in the treatment of patients as preoperative supplement, or used alone for unresectable and(or) metastatic gastrointestinal stromal tumor (GIST).
METHODS
A total of 30 cases with advanced GIST were proved pathologically. Among them,
[Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE
To evaluate the efficacy and safety of imatinib mesylate in the treatment of patients as preoperative supplement, or used alone for unresectable and/or metastatic gastrointestinal stromal tumors (GIST).
METHODS
A total of 51 cases with advanced GIST were proved pathologically. Among them,
Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
Imatinib mesylate and perifosine are two relatively new drugs that have improved outcomes for patients with gastrointestinal stromal tumors in recent years. The ocular side effects of these two drugs are discussed in this chapter. The most common ocular side effect associated with imatinib mesylate
[Gastrointestinal stromal tumor (GIST): case report].
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
The authors report a case of a male patient in his forties with progressive abdominal pain associated with weight loss, dyspnea, and edema of the inferior limbs, culminating in a surgical acute abdomen. A segmental enterectomy containing a lesion of about 10 cm in diameter was performed. It was
[A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate].
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
We report a patient who long had a complete response by chemotherapy with imatinib mesilate(IM)for locally recurrent gastrointestinal stromal tumor(GIST)of the stomach. On July 2000, a 58-year-old woman was pointed out to have anemia in the course of surveillance for malignant melanoma of skin.
A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE
This prospective, multicenter, phase 2 study evaluated the efficacy and safety of imatinib mesylate and assessed KIT and PDGFRA gene mutation status in Korean patients with gastrointestinal stromal tumors (GISTs).
METHODS
Forty-seven patients with pathologically proven KIT-positive
Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE
Imatinib mesylate (IM) is effective in metastatic gastrointestinal stromal tumor (GIST) patients; however, disease progression eventually occurs due to IM resistance or intolerance. Treatment options include IM escalation or a direct shift to sunitinib, but comparison of these strategies
Interventional digital subtraction angiography for small bowel gastrointestinal stromal tumors with bleeding.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE
To retrospectively evaluate the diagnostic efficacy of interventional digital subtraction angiography (DSA) for bleeding small bowel gastrointestinal stromal tumors (GISTs).
METHODS
Between January 2006 and December 2013, small bowel tumors in 25 consecutive patients undergoing emergency
Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
BACKGROUND
About 80% of patients with gastrointestinal stromal tumor (GIST) experience tumor recurrence or metastasis after a prior radical resection, and the most common metastatic site is the liver. Imatinib mesylate has been proven to be effective in advanced GIST. The current pilot study was
[Clinical characteristics and prognostic analysis of 45 patients with high-risk gastrointestinal stromal tumors].
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE
To investigate the clinical characteristics and prognosis factors of primary resectable high-risk gastrointestinal stromal tumors (GIST).
METHODS
The clinicopathological and follow-up data of 45 patients with primary resectable high-risk gastrointestinal stromal tumors between January 2002
Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
OBJECTIVE
To report the case of a patient affected by gastrointestinal stromal tumors (GIST) who developed cutaneous adverse drug reactions during treatment with imatinib and lansoprazole.
METHODS
After 2 months of treatment with imatinib 400 mg/day, a 60-year-old white female affected by GIST
[A case of recurrent gastrointestinal stromal tumor with complete response from treatment with reduced dose of imatinib mesylate].
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
We report a patient who had a complete response by treatment with 200 mg of imatinib mesylate daily for peritoneal recurrences of gastrointestinal stromal tumor(GIST)of the stomach. On March 2007, a 68-year-old woman underwent distal gastrectomy for GIST of the stomach. On May 2007, peritoneal
Association of hepatic nuclear factor 4 alpha gene polymorphisms with free Imatinib plasma levels and adverse reactions in Chinese gastrointestinal stromal tumor patients.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
La base de datos de hierbas medicinales más completa respaldada por la ciencia
- Funciona en 55 idiomas
- Curas a base de hierbas respaldadas por la ciencia
- Reconocimiento de hierbas por imagen
- Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
- Leer publicaciones científicas relacionadas con su búsqueda
- Buscar hierbas medicinales por sus efectos.
- Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.
Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.
